Desmopressin: Safety Considerations in Patients with Chronic Renal Disease

By Sica Domenic A.   Gehr Todd W.B.  

Drug Safety, Vol. 29, Iss. 7, 2006-01 ,pp. : 553-556

Adis International

Access to resources Recommend Favorite

Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease – pathophysiological considerations

By Rudnicki M   Mayer G  

Pharmacogenomics, Vol. 4, Iss. 2, 2003-03 ,pp. : 153-162

Future Medicine

Access to resources Recommend Favorite

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

By Brophy Donald F   Ripley Elizabeth BD   Holdford David A  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1461-1469

Informa Healthcare

Access to resources Recommend Favorite

A site-specific polymeric drug carrier for renal disease treatment

By Kishida A.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 12, 2003-12 ,pp. : 611-613

Elsevier

Access to resources Recommend Favorite

Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy: Special Considerations in Pediatric Patients

By Veltri M.A.  

Pediatric Drugs, Vol. 6, Iss. 1, 2004-01 ,pp. : 45-65

Adis International

Access to resources Recommend Favorite